Merck research division
Executive Summary
Four senior VPs and two VPs named. Burton Christensen, PhD, moves to senior VP-chemistry; Stanley Fidelman to senior VP-basic chemistry; Marvin Jaffe, MD, to senior VP-medical affairs; and Charles Leighton, MD, to senior VP-regulatory affairs worldwide. Arthur Patchett, PhD, appointed to newly-created position of VP-exploratory chemistry and Leslie Lars Iversen, MD, promoted to VP-Neuroscience Research Center, U.K.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.